Lys52
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys52  -  Tip60 (human)

Site Information
VHYIDFNkRLDEWVT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 474868

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 )
Disease tissue studied:
colorectal cancer ( 3 ) , colorectal carcinoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
vorinostat ( 4 )

References 

1

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

2

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

3

Possemato A (2010) CST Curation Set: 9462; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

4

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

5

Li Y (2007) CST Curation Set: 2376; Year: 2007; Biosample/Treatment: cell line, SW480/untreated &'||' nicotinamide; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info